Dosimetric Feasibility of Hypofractionated Radiation Therapy with Simultaneously Integrated Central Boost for Retroperitoneal Sarcoma

Background

Retroperitoneal sarcomas (RPS) are rare malignancies that pose challenges due to their large size and proximity to organs-at-risk (OARs). Compared to conventional 5-week radiation therapy (RT), hypofractionated RT (HFRT) offers a shorter alternative with potential biologic benefit, and simultaneous integrated boost (SIB) can increase delivered dose. We evaluated the dosimetric feasibility of HFRT with a central tumor SIB for bulky RPS.